Venture capital fund
Every published round Medicxi took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Medicxi has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Medicxi, as distinct from the investments it has made.
Companies Medicxi has backed that another company then bought. An exit for the holding, not a deal Medicxi did.
Stories naming Medicxi. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sanofi is buying Vicebio for up to US$1.6 billion in the biggest-ever exit of Australian university IP, with UQ keeping equity; the article also recalls the Inflazome and Spinifex sales and Vicebio's Medicxi seed.
Blackbird's annual review letter recaps a year of investing: sums deployed across dozens of rounds, distributions to its investors, four new investment-team members introduced, and foundation and community program highlights.